The safety and efficacy of etelcalcetide for the treatment of secondary hyperparathyroidism compared with cinacalcet

The safety and efficacy of etelcalcetide for the treatment of secondary hyperparathyroidism compared with cinacalcet - The safety and efficacy of etelcalcetide compared with cinacalcet

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000028041

Enrollment

Registered

2017-07-02

Start date

2017-07-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients on maintenance hemodialysis treated with cinacalcet for secondary hyperparathyroidism

Interventions

etelcalcetide dosage (2.5 - 15mg/every hemodialysis session) 12 months cinacalcet dosage (12.5 - 100mg/day) 12 months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with secondary hyperparathyroidism who are undergoing maintenance hemodialysis

Exclusion criteria

Exclusion criteria: Nothing

Design outcomes

Primary

Measure	Time frame
iPTH, Ca, P, side effect, dosage of etelcalcetide and vitamin D	—

Secondary

Measure	Time frame
Bone mineral density (0, 6, 12 months) BAP, TRACP (0, 6, 12 months) ABI and PWV, IMT (carotid ultrasound) ACI and ACAI (abdominal CT) (0, 12 months)	—

Countries

Japan

Contacts

Public ContactTakahiro Yajima

Matsunami general hospital Department of nephrology

yajima5639@gmail.com058-388-0111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026